Posted by Michael Wonder on 21 Sep 2021
Incyte announces U.S. FDA approval of Opzelura (ruxolitinib) cream, a topical JAK inhibitor, for the treatment of atopic dermatitis
21 September 2021 - Opzelura is the first and only topical Janus kinase inhibitor approved in the United States.
Incyte today announced that the U.S. FDA has approved Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable.
